Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834055 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL24448809 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL21038564 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL17834053 | 1.00 | LMNA (0.33) | LMNACYP2C9TSHRANPEPCNR2 | |
| SCHEMBL4835227 | 0.96 | TSHR (0.38) | LMNACYP2C9TSHRDPP4 | |
| SCHEMBL4845201 | 0.94 | TSHR (0.36) | LMNACYP2C9TSHR | |
| SCHEMBL4844966 | 0.86 | TSHR (0.41) | TSHR | |
| SCHEMBL102291 | 0.86 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL14652016 | 0.86 | LMNA (0.36) | LMNACYP2C9 | |
| SCHEMBL10974716 | 0.84 | ANPEP (0.32) | ANPEPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62030191-A | — | — | None | — | — | JP | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| WO-2020210938-A1 | QUINAZOLINE DERIVATIVES AS CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| CN-108271909-A | Oral delivery product including three-dimension object | 加优有限责任公司 | 2018-07-13 | — | — | CN | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20030155836-A1 | SMALL-SIZE MOTOR | UDA SHIGENORI (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-0977720-B1 | PERFUMES COMPRISING 3-ALKYLCYCLOALKANOLS | QUEST INT (NL) | 2002-06-19 | — | — | EP | disclosed |
| US-6313087-B1 | PERFUME COMPOSITION COMPRISING MIXTURE OF FRAGRANCE MATERIALS, INCLUDING AT LEAST ONE 3-ALKYLCYCLOALKANOL, PROVIDING MUGUET-TYPE ODOR NOTE TO SAID COMPOSITION | QUEST INTERNATIONAL BV (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2000036933-A1 | USE OF N-NEOHEXYL-α-ASPARTYL-L-PHENYLALANINE METHYL ESTER AS A FLAVOR MODIFIER | THE NUTRASWEET COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
| EP-0977720-A1 | PERFUMES COMPRISING 3-ALKYLCYCLOALKANOLS | QUEST INTERNATIONAL B.V. (NL) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047842-A1 | PERFUMES COMPRISING 3-ALKYLCYCLOALKANOLS | QUEST INTERNATIONAL B.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0209617-B1 | SMALL-SIZE MOTOR | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-01-29 | — | — | EP | disclosed |
| JP-S6230191-A | LUBRICANT | MATSUSHITA ELECTRIC IND CO LTD | 1987-02-09 | — | — | JP | disclosed |
| EP-0209617-A1 | Small-size motor | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1987-01-28 | — | — | EP | disclosed |
| JP-S06230191-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | LMNA 2777/4885CYP2C9 2542/4885TSHR 2658/4885 |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | LMNA 3947/4885CYP2C9 743/4885TSHR 2977/4885 |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | LMNA 4803/4885CYP2C9 4174/4885TSHR 720/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | LMNA 4803/4885CYP2C9 4174/4885TSHR 720/4885 |
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | LMNA 2760/4885CYP2C9 3800/4885TSHR 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.